Table 3.

Product label (PL) for the subcutaneous administration of LMWHs in the treatment of a thromboembolic disease (PL as of 1 November 2008)

LMWH	Dalteparin	Enoxaparin	Tinzaparin*
Acute coronary syndromes	120 IU kg−1 twice a day to a maximum of 10 000 IU twice a day	1 mg kg−1 twice a day†	Not indicated
Venous thromboembolic disease	100 IU kg−1 twice a day or 200 IU kg−1 daily‡	1 mg kg−1 twice a day or 1.5 mg kg−1 daily	175 IU kg−1 daily
Maximum dose	Refer to each indication	NR	NR
Individualization based on renal function	NR	1 mg kg−1 daily if CLCR <30 ml min−1§	Contraindicated if age >90 years with a CLCR≤60 ml min−1§
Individualization based on age	NR	NR†	Contraindicated if age >90 years with a CLCR≤ 60 ml min−1§
Individualization based on anti-Xa activity	NR	NR	NR

^*Tinzaparin is not licensed for use in Australia.

^†For the treatment of acute ST-segment elevation myocardial infarction in the US for subjects ≥ 75 years of age, the dose is 0.75 mg kg⁻¹ every 12 h. The PL was updated to incorporate these changes in Australia and NZ during the recruitment period. There is no dose reduction in the UK.

^‡Dose approved in all countries except Australia. The maximum dose is 18 000 IU daily.

^§CL_CR= creatinine clearance, assumed to be calculated using the Cockcroft-Gault equation where total body weight is the body size descriptor used [33]. IU, International units; NR, not recommended in the product label.